A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

Protocol No
ECOG-EA8212-BRIDGE
Staff Member
Scott Johnson
Phase
III
Summary

This study is being done to answer the following question:
Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual BCG therapy?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer. The usual approach is defined as care most people get for bladder cancer.

Objective
Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL